Skip to main content

Table 2 Depicts the clinical significance of different lncRNAs in ovarian cancer

From: Role of different non-coding RNAs as ovarian cancer biomarkers

lncRNAs in ovarian cancer Location Length Clinical Significance Reference
H19 Chr11p15.5 2.3 In ovarian cancer, when H19 is highly expressed it triggers migration and invasion of tumor cells [61]
HOTAIR Chr12.q13.13 2.2 HOTAIR plays crucial role in chemoresistance and its increased sensitivity towards cisplatin causes autophagy in OC [62]
X inactivate-specific transcript (XIST) ChrX 17 XIST is found to be a potent biomarker for patients who respond to first-line chemotherapy because a high affinity is found between regulation of XIST and patient response to chemotherapy using paclitaxel. [63]
UCA1 Chr19p13.12 1439 UCA1 is a dominant biomarker for several cancer types. Up-regulation of UCA1 is linked with progression-free survival (PFS) in ovarian cancer patients. (Hong, Hou [64])
MALAT-1 Chr11q13 > 8000 nucleotides Wnt/β-catenin signaling pathway is affected by; HOTAIR, MALAT-1 is, therefore, downregulation of MALAT-1 is used to inhibit OC cell viability, migration, and invasion, [65]
Plasmacytoma variant translocation 1 (PVT1) PVT1 Chr8q24.21 1716 nucleotides Progression of ovarian cancer is supported by PVT1 by silencing miR-214. [66]
GASS 1q25.1.10 0.7 The expression of GAS5 is more prevalent in EOC than in normal ovarian epithelium tissue. [67]
Homeobox protein D cluster antisense RNA 1 (HOXD-AS1 Chr2q31.2   Raised levels of HOXD-AS1 were adversely correlated with PFS and OS of EOC patients. [68]
Sprouty RTK signaling antagonist (SPRY4-IT1) Chr5q31.3 708 Progression of ovarian cancer might occur due to SPRY4-IT1 downregulation [119]. But still, the mechanism of this long codinglncRNAA is complicated, whether it acts as a tumor suppressor or an oncogene in ovarian tissue [69]